The most commonly reported side effects of tesamorelin include product dose omission issue, arthralgia, and injection site pain, based on 3,362 FDA adverse event reports from 2009 to 2025. 5.2% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for tesamorelin.
These are voluntary reports and do not establish that tesamorelin caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside tesamorelin. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
7.7% of tesamorelin adverse event reports involve female patients and 37.4% involve male patients. The largest age group is adult at 91%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking tesamorelin when the adverse event was reported.
Showing 15 of 62 indications
Tesamorelin is sold under the brand name Egrifta.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.